Novartis AG

Myelofibrosis is a chronic, debilitating myeloproliferative disorder characterized by progressive anemia, bone marrow fibrosis, splenomegaly, and constitutional symptoms.

Fampyra to improve walking speed in MS; Lodalis for hypercholestrerolemia; Saphris atypical antipsychotic; Other new products (Arzerra, Durela, Luxiq, Mozobil and Zelboraf); new generics, new indications, new dosage forms and Health Canada advisories.

New drugs, new indications, recent Health Canada advisories, new dosage forms, and new generics.

Until now, only twice-daily inhaled LABAs for COPD have been available in Canada.

Treatment with exemestane and everolimus may signal new approach

Spotlight on drugs in late-stage development in Canada.

IBM and Novartis have established the NCD Challenge, a competition among a number of the world's leading universities. It is designed to tap the inventiveness of students to find new ways to address the rise of non-communicable diseases in both developing and developed countries.